AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* patients ≥ 18 years with tissue-based diagnosis of mCRC
* ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.)

Exclusion Criteria:

* Due to the non-interventional design of this registry, there are no specific exclusion criteria

• DERIVEDHuemer F, Piringer G, Eisterer W, Heibl S, Rumpold H, Woll E, Schreil G, Sliwa T, Winder T, Prager G, Grunberger B, Moik F, Amann A, Taghizadeh H, Niedersuss-Beke D, Greil R, Weiss L. AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer. Future Oncol. 2026 Apr;22(9):1047-1053. doi: 10.1080/14796694.2026.2644463. Epub 2026 Mar 20. PMID 41860053